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INTRODUCTION
A growing body of research indicates that the experience of chronic non-cancer pain (CNCP) and risky patterns of alcohol use may be linked (Egli et al., 2012; Zale et al., 2015) . Up to one-quarter of people seeking treatment for chronic pain report excess alcohol use (Kim et al., 2013; Lawton and Simpson, 2009 ) and more than two-fifths of problem-drinkers report experience of moderate-to-severe pain in the past month (Brennan et al., 2005) . Among the potential explanations for the patterns of co-occurrence are that pain conditions develop as a result of intoxication-related injuries or damage, that alcohol is used to self-medicate pain or other stressors, and that stress from chronic pain increases any predisposition to drink excessively (Egli et al., 2012; Ilgen et al., 2010) . It is also possible that the comorbid problems that are common among people living with CNCP, such as depression, anxiety and sleep disorders, are also linked to problematic alcohol use. There is no well-defined temporal relationship between the onset of risky patterns of alcohol use and onset of CNCP. Some have postulated that there may be shared neural circuitry for experience of pain and alcohol reinforcement, so that neural dysregulation from pain may increase vulnerability to alcohol problems and vice versa (e.g., Egli et al., 2012) . Others have suggested that the relationship may be bidirectional, potentially leading to greater alcohol consumption and poorer pain outcomes over time (e.g., Zale et al., 2015) .
Despite these suggestions, synthesis of the literature suggests that the presumption of a linear relationship between increased alcohol consumption and poorer pain outcomes for people with CNCP might not be accurate. Population-based studies indicate that compared to abstinence, low-to-moderate alcohol consumption is associated with decreased likelihood of experience of chronic pain conditions, better quality of life and physical functioning, and lower pain ratings (Booker et al., 2003; Gorman et al., 1987; Hestbaek et al., 2006; Kim et al., 2013; Kondo et al., 2007; Macfarlane and Beasley, 2015; Rivara et al., 2008) . Increasingly, the relationship between alcohol use and pain is being described as a 'U-' or 'Jshaped' curve, with those drinking at moderate levels having fewer issues related to pain than either excess use or abstinence (Macfarlane and Beasley, 2015; Zale et al., 2015) . This pattern is consistent with relationships between alcohol use and other health outcomes such as cardiovascular disease and all-cause mortality (Plunk et al., 2014; Rehm et al., 2001 ).
However, these studies typically focused on specific pain conditions reducing generalisability and relied on dichotomous measures of alcohol use. Further, demographic (e.g., age and gender), mental health and substance use characteristics that are independently associated with both alcohol consumption patterns and chronic pain were not consistently controlled for in previous studies (Brennan et al., 2005; Zale et al., 2015) .
The use of alcohol to alleviate or cope with pain may exacerbate existing medical conditions, lead to acute cognitive impairment, increase the risk of injury from intoxication, delay helpseeking and increase the risk of adverse interactions with other analgesics (Brennan et al., 2005) . Given rising rates of opioid analgesic prescriptions (International Narcotics Control Board, 2009 ) and evidence of increasing alcohol consumption with ageing populations (e.g., Australian Institute of Health and Welfare, 2014) , it is critical to test the nature of the relationship between alcohol consumption and experience of pain when pharmaceutical opioids are present. Accordingly, the aims of this study were to use data from a cohort of people living with CNCP who have been prescribed pharmaceutical opioids in order to:
1. Examine the patterns of risky drinking and prevalence of alcohol use disorders (AUD) by sex;
2. Examine the relationships between different patterns of drinking and demographic characteristics, mental and physical health, substance use, and pain conditions; and 3.
Examine whether recent drinking patterns are independently associated with (a) pain severity, (b) pain interference and (c) pain coping, after controlling for the contribution of shared risk factors such as demographic characteristics, mental and physical health and substance use disorder history.
METHODS
The Pain and Opioid IN Treatment (POINT) study is a prospective cohort of people who have been prescribed opioids for CNCP (Campbell et al., 2014) . The methodology and characteristics of this cohort have been described in detail elsewhere (Campbell et al., , 2014 . This study utilises data collected at baseline.
Ethics approval
The study was approved by the Human Research Ethics Committee of UNSW Australia (HREC reference: # HC12149). The study also received A1 Australian National Pharmacy Guild Approval to approach pharmacists to assist with recruitment of participants (Approval n. 815).
Formation of the POINT cohort
Participants were eligible for the POINT cohort study if they and having taken such opioids for CNCP for more than 6 weeks.
A history of injecting drug use was not an exclusion criterion, but people currently prescribed pharmaceutical opioids for opioid substitution therapy (OST) for heroin dependence or for cancer were not eligible.
POINT participants were recruited through community pharmacies across Australia. From a database of 5,745 community pharmacies, 5,332 pharmacies were contacted by the study (92.8%). In total, 35% of all Australian pharmacies contacted by the study agreed to participate in recruitment.
Patients who fit the above criteria were given a flyer about the study by the pharmacist. Potential participants could opt to have the pharmacist send their details to researchers, or they could contact the research team directly. Pharmacists were reimbursed $20 for each eligible participant they referred into the study.
Approximately 2,700 participants were referred into the wider POINT study. Of the 2,091
participants assessed for eligibility, 90% (n=1,873) were eligible and a total of 1,514 completed baseline POINT study interview (201 refused after being deemed eligible and 100 were unable to be contacted).
Interview and data collection procedure
Phone interviews took 1-1.5 hours to complete and were conducted by assistants who had a minimum 3-year health or psychology degree. Interviewers had received training in the survey instrument and were provided glossaries of chronic pain medications and conditions (Campbell et al., 2014) . In addition to the telephone interview, all participants were asked to complete a 7-day diary of all past-week medications and a short self-complete survey.
Participants were reimbursed $40 for the interview.
Measures
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The measures, tools, and domains collected by the POINT study were based on recommendations of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT; Dworkin et al., 2005; Turk et al., 2003) . Full details of the measures used in the study have been reported elsewhere (Campbell et al., 2014) ; however, brief summaries of measures used in the current analyses are provided below.
Demographic characteristics.
The following key demographic variables were included in the analyses: age, sex, unemployment, and receiving a weekly income <$400AUD per week (equivalent to receiving government benefits or pension). ). Participants were also asked to report whether they currently used tobacco daily.
Alcohol
Physical health.
Self-reported height and weight was converted into a Body Mass Index (BMI) score. A BMI score of 30 more indicates obesity and was used in the current study.
The Short Form 12 (SF12) physical functioning subscale was used to measure physical disability (Bjorner and Turner-Bowker, 2009 ). Australian population norms comprise a mean score of 50 and a SD of 10; a score 2 standard deviations below (30) was considered indicative of poor physical functioning (Sanderson K and G., 2002) . Participants were asked to identify the number of health services they had accessed in the last month (general practitioner, ambulance, emergency department, day procedure, physiotherapy, mental health services, specialist services, physical therapies, and complementary and alternative therapies). Participants were also asked if they had overdose on any drug in their lifetime and in the past 12 months, and whether alcohol was involved in the last overdose.
Pain and pain-related measures.
Participants were asked about lifetime and current pain conditions, including their age of onset. Past week pain severity, pain interference and relief from pain medications were measured using the short-form of the Brief Pain Inventory (Cleeland, 1991) , as a continuous score out of 10 (higher scores equivalent to greater intensity of pain and interference in daily functioning, respectively). The pain severity score is the mean of four individual items (how do you rate your pain 'at its worst', 'at its least', 'on average' and 'right now'), each rated on a scale 0-10 (where 0= 'no pain', and 10='pain as bad as you can imagine') (Cleeland, 1991) . The pain interference score is the mean of seven individual interference ratings (the extent to which pain interferes with general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life), each rated on a scale of 0 to 10 (where 0='does not interfere' to 10='completely interferes'). (Cleeland, 1991) . The Brief Pain Inventory also asks the patient to indicate the percentage of relief provided by pain treatments or medications in a single 10-point item, from 0% to 100%.
The Pain Self-Efficacy Questionnaire (Nicholas, 2007; Nicholas et al., 2008) comprises ten items that are rated by participants in terms of how confident they are that they can do each item despite the pain on a 6 point scale (where 0='not at all confident' and 6='completely confident'). This results in a total score from 0-60, with higher scores indicating greater confidence in managing life despite pain.
Opioid medication.
Daily oral morphine equivalent (OME) doses for the pharmaceutical opioids taken by the cohort were estimated following review and synthesis of a range of clinical guidelines . Current average daily dose (OME mgs/day) was calculated using opioid consumption from a one-week medication diary completed as part of the self-complete questionnaire mailed to participants. Participants were also asked about lifetime and past 12 month medication use.
Data analysis
All analyses were planned a priori independent of the data and conducted using STATA, iii. 'Non-risky drinkers' drank alcohol in the past 12 months, but not at risky levels (intake 4 or fewer standard drinks);
iv. 'Occasional risky drinkers' drank 5 or more standard drinks on a single occasion in the past 12 months, but not on a regular basis; and v. 'Regular risky drinkers' drank 5 or more standard drinks on a single occasion, on a weekly or more frequent basis in the past 12 months.
This categorisation of drinking frequency aligns with that reported in the Australian National Drug Strategy Household Survey (Australian Institute of Health and Welfare, 2014) , with the exception of distinguishing between lifetime abstainers and former drinkers (a common practice in alcohol research (e.g., Liang and Chikritzhs, 2013) . Multinomial regression was used to examine potential differences in the demographic, mental health, physical health, substance use, and pain correlates of drinking group membership. Relative risk ratios (RRRs)
were reported for bivariate comparisons between groups, with the 'non-risky drinkers' as the referent category. This coding was used on the basis of a U-or J-curve relationship between alcohol use and pain-related functioning (Zale et al., 2015) .
Our study had a specific research question based on the Zale et al. (2015) review;
specifically, to explore whether recent drinking patterns are independently associated with pain, after controlling for the contribution of shared risk factors such as demographic characteristics, mental and physical health and substance use disorder history. As such, the variables included in our models were based on recommendations in this paper. Hierarchical nested regression models were used to determine the independent contribution of drinking group pattern (based on past 12 months patterns of drinking and risk) to (i) pain severity, (ii) pain interference and (iii) pain coping, while controlling for the contribution of shared risk factors: specifically, demographics (age, sex, income below AUD400 per week), opioid dose, physical health (SF12 score, BMI obese), mental health (past 12 month depression, past 12 month anxiety) and a lifetime history of other substance use disorders (ICD criteria for illicit substances, benzodiazepines and pharmaceutical opioids use disorders). 'Non-risky drinkers'
were the referent category.
RESULTS
Sample characteristics
A total of 1,424 people with CNCP were included in this study. The sample was two-thirds female (56%) with median age was 58 years (IQR 48-67) and high levels of socio-economic disadvantage. Just under half (49%) were unemployed and over half (54%) reported low income (<$400AUD per week; Table 2 ).
There were high levels of comorbid mental and physical health problems, with substantial proportions reporting past 12 month depression (42%) and anxiety (27%), just under onethird (31.2%) reporting daily smoking and three-fifths (27.6%) reporting an SF12 score indicative of poor physical functioning (i.e. scoring 2 standard deviations below the general population average; Table 2 ).
The most commonly reported lifetime pain conditions were chronic back/neck problems (79.7%), arthritis/rheumatism (67.9%), and frequent/severe headaches (44.9%). A history of multiple pain conditions was common, with participants reporting a median of two pain conditions (IQR 2-3) in the past twelve months ( Table 2 ). The pharmaceutical opioids prescribed most commonly to the sample were oxycodone (61%), codeine (24%) and buprenorphine (22%). The median total opioid dose was 75 OME mgs/day, although doses are variable in the cohort , with 40% of the sample reporting doses >90 OME mg/day (and 15% receiving doses >=200 OME mg/day).
Seventeen percent of the sample had ever overdosed on a substance, and 3% had done so in the past 12 months. On average, participants reported a median of one overdose (involving any substance) in the past 12 months (IQR 1-2). Alcohol was involved in 18% of past 12 month overdoses.
Patterns of drinking and alcohol use disorders
Less than one-tenth of the sample reported no lifetime use of alcohol ('lifetime abstainers'; 7%, n=104). Over one-third (34%, n=488) were 'former drinkers' (i.e., lifetime alcohol use, but not in the past 12 months). The majority (61%) had drunk alcohol in the past twelve months; 34% of the total sample (n=488) were grouped as 'non-risky drinkers' (drank alcohol in the past twelve months, but not at risky levels), 16% (n=233) as 'occasional risky drinkers' (drank five or more drinks on a single occasion in the past 12 months, but not on a regular basis), and 8% (n=110) as 'regular risky drinkers' (drank 5 or more drinks on a single occasion, on a weekly or more frequent basis in the past 12 months).
Men reported significantly higher levels of alcohol consumption on all past 12 month measures of use and risk (Table 1) ; for example, men reported lower odds of being 'lifetime abstainers' than women, and had five-fold increased odds of being 'regular risky drinkers'.
Around a third of the sample (32.7%) reported a lifetime AUD (49.3% of men); 19.5% met criteria for lifetime harmful use (30.6% of men), and 13.1% met criteria for lifetime alcohol dependence (18.6% of men; Table 1 ).
Around one in seven participants reported that their experience of pain preceded that of problematic drinking. This was more common among men (approximately one in six) than women (OR 1.63; 95% CI: 1.20-2.01; Table 2 ). Of the 389 who drank alcohol in the past twelve months and were asked this item, 16% reported that they had used alcohol for their pain. There were no differences between men and women.
Demographic and clinical profiles of the drinking groups
'Lifetime abstainers' were more likely than 'non-risky drinkers' to be older, female, to report low incomes and higher levels of relief from their pain medication, and to have accessed fewer health services in the past month. By contrast, 'former drinkers' were more likely than 'non-risky drinkers' to be older, unemployed, taking higher opioid doses, to have poorer physical health scores, to report daily smoking, lifetime AUDs, and (past twelve month)
anxiety, to rate their quality of life as 'poor/very poor', to report multiple (past twelve month) pain conditions, higher pain severity and interference scores, and to have lower levels of pain self-efficacy ( Table 2 ).
The 'occasional risky drinkers' were more likely than the 'non-risky drinkers' to be younger, male, and unemployed, to have higher physical health scores (indicating better physical functioning), a history of illicit drug dependence, lifetime AUDs and daily smoking, past twelve month anxiety, chronic back/neck problems, and higher pain interference scores; they were less likely to report arthritis or rheumatism. The 'regular risky drinkers' group had similar demographic profiles to the 'occasional risky drinkers' when compared to the 'nonrisky drinkers' (i.e., 'regular risky drinkers' were also more likely to be younger, unemployed and substantially more likely to be male (OR 5.78; 95% CI: 3.53-9.48), compared to 'non-risky drinkers'). Regular risky drinkers' were substantially more likely than 'non-risky drinkers' to report a lifetime history of alcohol dependence (10% reported symptoms of an AUDs in the past 12 months), daily smoking, family history of alcohol problems, higher pain severity and interference scores, and lower levels of social support (Table 2) .
Is group membership independently associated with pain and pain coping, controlling for the contribution of shared risk factors?
3.4.1 Pain severity. The results of a hierarchical regression of predictors of pain severity (using 'non-risky drinkers' as the referent group) are presented in 
DISCUSSION
This study was uniquely placed to shed light on the relationship between pain and alcohol use in a large cohort of people with CNCP prescribed strong opioids, while taking into consideration a wide array of demographic characteristics, mental and physical health, and substance use behaviours. We found that 'former drinkers' typically displayed poorer clinical profiles when compared with 'non-risky drinkers', including higher levels of anxiety and lifetime AUDs, poorer quality of life, poorer physical health scores, higher pain severity and interference ratings and lower levels of pain coping. This group were typically older, with multiple pain conditions. 'Former drinkers' were more likely than 'non-risky drinkers' to report higher pain severity and interference ratings, and lower pain coping after controlling for demographics, mental health, physical health and substance use disorder history. We were unable to determine whether 'former drinkers' ceased drinking because of maturation, pain or ill health (the 'sick-quitter' hypothesis) in this study, although all of these are plausible explanations (Frisher et al., 2015; Ng Fat et al., 2013) .
At the other end of the spectrum, 'occasional risky drinkers' and 'regular risky drinkers' reported more social disadvantage and poorer physical health and substance use profiles (including lifetime AUDs) than 'non-risky drinkers'. These groups were typically younger, with fewer pain conditions, but reported higher pain severity and interference ratings.
'Occasional risky drinkers' and 'regular risky drinkers' reported higher levels of pain interference than 'non-risky drinkers' after controlling for confounders. It is important to stress that these data are correlational and cannot be taken as showing that moderate alcohol consumption improves pain outcomes. Rather, quitting drinking was associated with poorer physical health, and risky alcohol consumption was associated with higher levels of social disadvantage, compared to moderate drinking.
Pain may serve as a situational motivation for alcohol consumption. The self-medication hypothesis (i.e., that people use alcohol to alleviate pain) is based on alcohol's short-term dose-dependent analgesic effect as has been shown in experimental research; Perrino et al., 2008; Riley and King, 2009 ). Up to one-quarter of people enrolled in pain treatment and substance abuse treatment report using alcohol to cope with pain (Goebel et al., 2011; Sheu et al., 2008 ). In the current study, almost one in six past-year alcohol consumers reported that they used alcohol to cope with pain. Prospective research shows that risky alcohol consumption increases over time in those who report using alcohol to cope with pain (Brennan et al., 2005) . Others have suggested this escalation arises from the development of tolerance to alcohol's analgesic effects with chronic use, and/or the onset of alcohol withdrawal-induced hyperalgesia (Egli et al., 2012) . The current report's finding that (occasional and regular) risky drinking was associated with greater pain interference provides support for this idea.
A substantial minority of this cohort (8%) reported regular binge drinking in the past year (i.e. 5+ drinks on single occasion on weekly+ basis) (13% of men). This pattern increases the risks of acute harm. Pharmaceutical opioids have depressant actions on the central nervous system, leading to increasing sedation, motor impairment, and respiratory depression.
Concomitant use of opioids and other CNS depressants such as alcohol may interact, exacerbating existing medical conditions where contraindicated, and increasing the risk of acute harms. There is a large body of literature showing that alcohol intoxication is a risk factor for opioid overdose (e.g., Roxburgh et al., 2011; Warner-Smith et al., 2001) . Given that there is considerable use of benzodiazepines and other medications such as antidepressants in this cohort Nielsen et al., 2015) , overdose risk in this sample is an issue of concern. In this report, among the minority of participants who reported any recent (past year) overdose, alcohol was involved in 18% of recent overdoses. In the US, alcohol was involved in 19% of 'opioid pain reliever' emergency department visits, and 22% of 'opioid pain reliever'-related deaths (Jones et al., 2014) .
The harms of alcohol and pharmaceutical opioid use extend beyond acute use. Lifetime
AUDs may be more prevalent among people who use prescription opioids than in the general population (Jobski et al., 2012) . In this cohort of people with CNCP, we found riskier patterns of drinking in men compared to women (similar to population trends), but overall high levels of risky drinking in general. There was also a high prevalence of lifetime AUDs (33%), particularly among men (49%); 13% met criteria for lifetime alcohol dependence Research with chronic pain populations shows that a history of AUD predicts extra-medical prescription opioid use (Ives et al., 2006; Michna et al., 2004) , and a history of dependence on one drug class increases vulnerability to dependence on the other (Pergolizzi Jr et al., 2012) . Men may be more likely to consume alcohol to cope with pain (Brennan et al., 2005) , and the experience of pain predicts heavy drinking lapses following treatment for AUD (Staiger et al., 2013; Witkiewitz et al., 2015a Witkiewitz et al., , 2015b . The association observed between greater smoking and risky alcohol use highlights the concern of smoking-related illness further complicating the clinical outcomes for this group. 
Limitations
A key strength of this study was the large size of this community based sample of people with CNCP and the rich data that were collected on their clinical profiles. To assess representativeness of the POINT cohort, we have previously compared key characteristics (gender, age and type of opioid) of those enrolled in the study with the characteristics of all customers recorded as purchasing opioids in a random sample of 71 recruiting pharmacies and found striking similarities. Specifically, 52% were female (the POINT cohort was 55% female); and 7% were 18-34 years, 55% 35-64 years and 38% 65+ years (vs. 5%, 62% and 33% respectively, in the POINT cohort). Of these customers, 63% were prescribed oxycodone (vs. 62% in the POINT cohort), 16.5% prescribed morphine (vs. 15% in the POINT cohort), 21% prescribed fentanyl patches (vs. 15% in the POINT cohort) and 24% prescribed buprenorphine patches (vs. 21% in the POINT cohort). Although it is not possible to determine whether all the opioid customers recorded by these pharmacists had been taking these opioids for chronic pain, and for six weeks or more, the similarities are reassuring.
Nonetheless, data on onset of pain and AUD symptoms were collected retrospectively and therefore depend on participant recall. Potential biases may arise from the reliance on selfreport data and information on chronic medical illnesses or other health problems were not verified from patient records. All participants were informed that their responses would be de-identified and confidential, which generally enhances the validity of self-reported substance use (Darke, 1998) . As the data are cross-sectional we are unable to determine causality, or examine trajectories in pain severity and interference and alcohol use. The future analysis of longitudinal data collected in the POINT study may enable some of these questions to be answered.
Conclusions
Chronic pain and alcohol use are highly prevalent in the general population and are major clinical and public health issues. This study finds clear associations between alcohol use and pain severity and interference. Compared with moderate alcohol consumption, having ceased alcohol use or engaging in risky drinking are each associated with poorer pain outcomes.
Risky-drinking may a modifiable factor that, if addressed, might positively impact on pain outcomes. In the context of an increasing, ageing population of people with CNCP and comorbid physical and mental health problems, the interplay betewen alcohol use, pain and quality of life is likely to remain a critical area for futher work. The comorbidity of CNCP, substance use and other mental disorders is manifest as greater disability in daily functioning and greater complexity in treatment, requiring integration of alcohol and drug treatment services and pain services with primary care.
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